Form 8-K - Current report:
SEC Accession No. 0000059478-25-000129
Filing Date
2025-05-01
Accepted
2025-05-01 07:03:11
Documents
16
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lly-20250501.htm   iXBRL 8-K 50001
2 EX-99.1 q125lillysalesandearningsp.htm EX-99.1 170596
7 logoa31.jpg GRAPHIC 14287
  Complete submission text file 0000059478-25-000129.txt   481005

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lly-20250501.xsd EX-101.SCH 4497
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT lly-20250501_def.xml EX-101.DEF 19611
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lly-20250501_lab.xml EX-101.LAB 37995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lly-20250501_pre.xml EX-101.PRE 20830
18 EXTRACTED XBRL INSTANCE DOCUMENT lly-20250501_htm.xml XML 10543
Mailing Address LILLY CORPORATE CENTER DROP CODE 1094 INDIANAPOLIS IN 46285
Business Address LILLY CORPORATE CTR DROP CODE 1094 INDIANAPOLIS IN 46285 3172762000
ELI LILLY & Co (Filer) CIK: 0000059478 (see all company filings)

EIN.: 350470950 | State of Incorp.: IN | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06351 | Film No.: 25899349
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)